Evidence map›Paper›PMID 34283360›Full record

ArticleDigestive diseases and sciences2022

Clinical Characteristics and Treatment Response in Microscopic Colitis Based on Age at Diagnosis: A Multicenter Retrospective Study.

Amrit K Kamboj, Jessica McGoldrick, Eli Voth, Daniel Penrice, June Tome, Amandeep Gujral, Kaia Miller, Kristin E Burke, Darrell S Pardi, Hamed Khalili

Open access · hybridAbstract readMulticenter Study
In one paragraph

Article in Digestive diseases and sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Amrit K KambojDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Jessica McGoldrickDivision of Gastroenterology and Hepatology, Massachusetts General Hospital, Boston, MA, USA.
Eli VothDepartment of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Daniel PenriceDepartment of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
June TomeDepartment of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Amandeep GujralDivision of Gastroenterology and Hepatology, Massachusetts General Hospital, Boston, MA, USA.
Kaia MillerDivision of Gastroenterology and Hepatology, Massachusetts General Hospital, Boston, MA, USA.
Kristin E BurkeDivision of Gastroenterology and Hepatology, Massachusetts General Hospital, Boston, MA, USA.
Darrell S PardiDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Hamed KhaliliDivision of Gastroenterology and Hepatology, Massachusetts General Hospital, Boston, MA, USA. hkalili@mgh.harvard.edu.ORCID 0000-0002-7956-6941
Mayo Clinic in Arizona · USMassachusetts General Hospital · USKarolinska Institutet · SE

Funding

Medications, the gut microbiota, and risk of microscopic colitisR01AG068390 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI KHALILI, HAMED · 2020 to 2024
$2.5M
NIA NIH HHS R01 AG068390
6 · The paper itself

Abstract

backgroundMicroscopic colitis (MC) primarily affects older adults; thus, data in younger patients are scarce.

aimsTo compare clinical characteristics and treatment response by age at diagnosis.

methodsThis retrospective cohort study was performed at Mayo Clinic and Massachusetts General Hospital. Patients were chosen consecutively using established databases. Patients were 'younger' if age at diagnosis was ≤ 50 years and 'older' if age > 50 years. Treatment outcomes were captured for induction (12 ± 4 weeks), based on the total number of daily stools, and defined as remission (complete resolution), response (≥ 50% improvement), non-response (< 50% improvement), and intolerance. Patients were considered 'responders' if they had remission or response and 'non-responders' if they had non-response or intolerance.

resultsWe included 295 patients (52 younger, 243 older). There were no differences in sex, race, MC subtype, and diarrhea severity between groups (all P > 0.05). Younger patients were more likely to have celiac disease (17.3% vs. 5.8%, P = 0.01), while older patients had higher BMI (mean 25.0 vs. 23.8 kg/m

conclusionsThere are no significant differences in MC treatment response based on age or disease subtype. These findings support treating patients with MC based on symptom severity rather than age.

Indexed as

Colitis, CollagenousColitis, LymphocyticColitis, MicroscopicAgedAge FactorsBudesonideHumansMiddle AgedRetrospective StudiesBudesonideBismuth subsalicylateBudesonideCollagenous colitisDiarrheaLoperamideLymphocytic colitisMesalamineMicroscopic colitis

Identifiers

PMID34283360
PMCPMC9236988
OpenAlexW3184530572

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.